Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Adjuvant CDK4/6 Inhibition Is Not Yet a Clear Winning Strategy in HR+/HER2- Breast Cancer

May 10th 2021

Conflicting results from the phase 3 monarchE, PENELOPE-B, and PALLAS trials have thrown the role of adjuvant CDK4/6 inhibition into question in patients with high-risk, early-stage hormone receptor–positive, HER2-negative breast cancer.

RxPONDER Trial in HR+ Operable Breast Cancer

May 10th 2021

Priyanka Sharma, MD, and Lajos Pusztai, MD, PhD, review recent results from the RxPONDER trial looking at the predictive value of the Oncotype DX RS on benefit of adjuvant chemotherapy in women with lymph node-positive, HR+, HER2- breast cancer.

HR+ Breast Cancer: Oncotype DX RS and TAILORx

May 10th 2021

Experts in breast cancer provide a historic perspective on the use of the Oncotype DX recurrence score (RS) in patients with HR+, HER- breast cancer and review practical implications from the TAILORx trial.

Dr. de Ligt on Using Symptom Burden to Tailor Follow-Up Care in Breast Cancer Survivors

May 8th 2021

Kelly de Ligt, PhD, discusses subgroups of symptom burden seen in breast cancer survivors.

Dr. Dang on Cardiac Safety With Pertuzumab/Trastuzumab in Early-Stage HER2+ Breast Cancer

May 8th 2021

Chau T. Dang, MD, discusses the safety profile of pertuzumab plus trastuzumab in patients with HER2-positive locally advanced, inflammatory, or early-stage breast cancer.

High-Grade ILD Prevention With Trastuzumab Deruxtecan Includes Early Detection, Optimal Management in HER2+ Metastatic Breast Cancer

May 8th 2021

Effective early detection and optimal management are critical in preventing high-grade interstitial lung disease, a treatment-related adverse effect of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive metastatic breast cancer.

HER2+ Breast Cancer With Immune-Related Gene Signatures May Be Eligible for De-Escalation Approaches

May 8th 2021

Distinct gene signatures, with the exception of estrogen receptor signaling and BRCAness, are associated with pathologic complete response and invasive disease-free survival, in patients with HER2-positive breast cancer who received trastuzumab and pertuzumab alone or in combination with paclitaxel.

Dr. Powell on the Risk of ILD with Trastuzumab Deruxtecan in HER2+ Breast Cancer

May 8th 2021

Charles Powell, MD, MBA, discusses the risk of interstitial lung disease in patients with HER2-positive metastatic breast cancer treated with trastuzumab deruxtecan.

Datopotamab Deruxtecan Shows Encouraging Preliminary Safety, Efficacy in TNBC

May 8th 2021

The differentiated TROP2-directed antibody-drug conjugate datopotamab deruxtecan was found to have promising antitumor activity with a manageable safety profile in heavily pretreated patients with triple-negative breast cancer.

Retesting for HER2 Upon Breast Cancer Relapse May Provide New Therapeutic Opportunities

May 8th 2021

Approximately 30% of breast cancer tumors can covert from, or to, HER2-low status, underscoring the need to retest for HER2 expression upon relapse.

Shorter Duration of Adjuvant Trastuzumab Shows Long-Term Survival Benefit in Select HER2+ Early Breast Cancer

May 8th 2021

Although administering trastuzumab for 1 year in patients with HER2-positive early breast cancer continues to be standard, a 9-week de-escalation approach may be a reasonable option in a large proportion of the real-world HER2-positive population.

Dr. Voorwerk on Outcomes with Atezolizumab Plus Carboplatin in Metastatic Lobular Breast Cancer

May 7th 2021

Leonie Voorwerk, discusses outcomes with the combination of atezolizumab plus carboplatin in metastatic lobular breast cancer, which was evaluated as part of the phase 2 GELATO trial.

Dr. Bachelot on the Role of Tucatinib in HER2+ Breast Cancer With CNS Metastases

May 7th 2021

Thomas Bachelot, MD, PhD, discusses the role of the combination of tucatinib plus trastuzumab and capecitabine in patients with HER2-positive breast cancer who have central nervous system metastases.

Dr. Conte on Outcomes With 1 Year Vs 9 Weeks of Adjuvant Trastuzumab in HER2+ Breast Cancer

May 7th 2021

Pier Franco Conte, MD, discusses long-term outcomes with 1 year vs 9 weeks of treatment with adjuvant trastuzumab in patients with HER2-positive early breast cancer.

Ribociclib/Endocrine Therapy Improves OS Regardless of Age in Advanced HR+/HER2- Breast Cancer

May 7th 2021

Ribociclib plus endocrine therapy improved overall survival and post-progression outcomes in pre- or postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer irrespective of age.

Atezolizumab Plus Carboplatin Induces Early Efficacy Signals in Invasive Lobular Breast Cancer

May 7th 2021

Treatment with atezolizumab plus carboplatin demonstrated early clinical activity in patients with metastatic invasive lobular breast cancer, with slight trends toward increased clinical benefit in patients with triple-negative ILC and responders with higher PD-L1 expression, according to initial findings of the non-randomized phase 2 GELATO trial.

Breast Cancer Survivors Need More Tailored Follow-Up Care

May 7th 2021

Post-treatment care for breast cancer survivors must be personalized to address each survivor’s unique experiences.

KATHERINE and FeDeriCa Trials Shift Standards in Early-Stage HER2+ Breast Cancer

May 6th 2021

Olwen Hahn, MD, discusses the clinical significance of the KATHERINE and FeDeriCa trials in the treatment of patients with early-stage HER2-postive breast cancer.

Navigating Neoadjuvant, Adjuvant Immunotherapy and ADCs in Metastatic TNBC

May 5th 2021

Although checkpoint inhibition has been shown to benefit some patients with metastatic triple-negative breast cancer, there is not yet a role for immune-based treatment in the neoadjuvant setting.

Dr. Hahn on the Impact of Trastuzumab Emtansine in HER2+ Breast Cancer

May 3rd 2021

Olwen Hahn, MD, discusses the impact of trastuzumab emtansine on the treatment of patients with HER2-positive breast cancer.